$SDGR is teaming up with $LLY to bring Eli Lilly’s AI-powered drug discovery platform (TuneLab) into Schrödinger’s LiveDesign software, giving researchers better tools to speed up drug design and prediction. This expands Schrödinger’s AI footprint in biotech and shows how big pharma is leaning into AI to stay ahead in R&D. Strong collaborations like this can boost adoption and signal deepening industry AI integration. But the big question remains, will this translate into real, profitable growth for both sides or just look good on slides?